<DOC>
	<DOCNO>NCT00667485</DOCNO>
	<brief_summary>The goal trial determine toxicity maximum dose rapamycin bevacizumab give together subject advance cancer . This study also look pharmacokinetics antitumor activity combination .</brief_summary>
	<brief_title>Rapamycin Plus Bevacizumab Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Metastatic unresectable solid tumor standard treatment exist longer effective Performance status 01 Measurable nonmeasurable disease Life expectancy least 12 week No anticipated need cancer treatment within next 4 week 18 year older Negative pregnancy test woman able child , agreement use medically accept birth control method receive study drug least 2 week stop , breast feeding Ability understand willingness sign write informed consent document No evidence bleed diathesis Patients without lung cancer receive anticoagulation treatment participate Adequate organ marrow function : ALT AST less equal 2.5 time institutional ULN ( less 5 time patient liver involvement ) hemoglobin least 9g/dL absolute neutrophil count least 1,500/µL platelet least 100,000/µL total bilirubin less equal 1.5 time institutional ULN creatinine less equal 1.5 time institutional ULN Prior treatment bevacizumab mTOR inhibitor allow . Prior treatment bevacizumab OR mTOR inhibitor ( include rapamycin ) allow . Patients grade 3 great side effect either bevacizumab mTOR inhibitor take part study . Chemotherapy Immunotherapy within 4 week study start Radiotherapy within 14 day study start Can receive investigational drug cancer treatment study ( exception androgen ablate agent patient prostate cancer ) . Patients squamous nonsmall cell lung cancer ( NSCLC ) Patients lung cancer lung metastasis : full dose anticoagulation take 325mg aspirin per day nonsteroidal antiinflammatory agent HIV positive patient receive combination antiretroviral therapy exclude due potential serious infection take marrow suppress agent Ongoing illness medical exclusion , include limited : active ongoing infection symptomatic congestive heart failure uncontrolled hypertension despite optimal medical management cardiac arrhythmia except paroxysmal atrial fibrillation psychiatric illness/social situation would limit compliance study requirement history organ allograft , bone marrow peripheral blood stem cell transplant know suspect allergy bevacizumab rapamycin seizure disorder treat steroid anticonvulsant therapy thrombotic embolic event within 6 month start study pulmonary hemorrhage/bleeding within 12 week start study ( grade 3 event within 4 week first dose drug ) . Patients history pulmonary hemorrhage/bleeding full dose anticoagulation . pulmonary fibrosis interstitial lung disease serious nonhealing wound , ulcer bone fracture Major surgery , open biopsy traumatic injury within 4 week start study drug anticipate need major surgery onstudy current use herbal supplement rifampin ( rifampicin ) prior history hypertensive crisis hypertensive encephalopathy history myocardial infarction unstable angina within 6 month start study know CNS disease significant vascular disease symptomatic peripheral vascular disease evidence bleed diathesis coagulopathy core biopsy minor surgical procedure ( except placement vascular access device ) within 7 day start study history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month study start proteinuria screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>